Live cell-based assay (L-CBA) and fixed cell-based assay (F-CBA) demonstrate superior sensitivity and specificity for acetylcholine receptor (AChR) antibody detection in myasthenia gravis (MG) compared with ELISA.
L-CBA showed a statistically significant but modest diagnostic advantage over F-CBA, confirming its role as the gold standard.
ELISA testing exhibited substantially lower specificity, resulting in a high false-positive rate, which warrants cautious interpretation in clinical practice.
For muscle-specific kinase (MuSK) antibody detection, all tests showed similar sensitivity and perfect specificity, indicating consistent performance across assay types.
